Bladder Cancer Chemosensitivity is Affected by Paraoxonase-2 Expression

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Bladder cancer remains a significant health concern with ongoing research into novel therapeutic targets.
• Paraoxonase-2 (PON2) is an enzyme whose role in cancer, particularly bladder cancer, is not fully elucidated.

Purpose of the Study:

• To investigate the functional role of paraoxonase-2 (PON2) in bladder cancer cell proliferation, migration, and response to chemotherapy.
• To determine the impact of PON2 modulation on reactive oxygen species (ROS) production and apoptosis-related caspase activation in bladder cancer cells.

Main Methods:

• T24 bladder cancer cells were manipulated for paraoxonase-2 (PON2) gene silencing (using shRNA) or overexpression.
• Cell proliferation, migration, reactive oxygen species (ROS) production, and caspase-3/caspase-8 activity were assessed.
• Cells were treated with cisplatin and gemcitabine, alone or in combination, to evaluate chemoresistance.

Main Results:

• Paraoxonase-2 (PON2) overexpression enhanced T24 cell proliferation and migration.
• Knockdown of paraoxonase-2 (PON2) reduced cell viability under chemotherapy and increased ROS production and caspase activation.
• Conversely, PON2 overexpression correlated with increased proliferation and reduced ROS/caspase activity when cells were treated with chemotherapeutic agents.

Conclusions:

• Paraoxonase-2 (PON2) significantly influences bladder cancer progression and chemoresistance.
• Modulating paraoxonase-2 (PON2) levels affects cancer cell behavior and susceptibility to chemotherapy.
• Paraoxonase-2 (PON2) emerges as a promising molecular target for developing novel bladder cancer therapies.